A Single-arm Multi-center Trial of BCMA/CD3 Bispecific Antibody for Relapsed/Refractory AL Amyloidosis or Newly Diagnosed AL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs CM 336 (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2025 New trial record